Neil S. Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil S. Zheng has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Vern Eric Kerchberger
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, USA
4 shared publications - Wei-Qi Wei
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, USA
4 shared publications - Douglas M. Ruderfer
Center for Digital Genomic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
2 shared publications - Evan L. Brittain
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN
2 shared publications - Hiral Master
Department of Health Sciences, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 shared publications - Jack H. Ching
Google, Mountain View, CA, United States
2 shared publications
Latest Publications
- Open Access
- 18 March 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (3)
A Computable Electronic Health Record ARDS Classifier and the Association Between the MUC5B Promoter Polymorphism and ARDS in Critically Ill Adults
- 18 March 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (3)
Open AccessA Computable Electronic Health Record ARDS Classifier and the Association Between the MUC5B Promoter Polymorphism and ARDS in Critically Ill Adults
- Open Access
- 24 January 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e71718
Capturing Real-World Habitual Sleep Patterns with a Novel User-centric Algorithm to Pre-Process Fitbit Data in the All of Us Research Program: Retrospective observational longitudinal study. (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Commercial wearables like Fitbits quantify sleep metrics using fixed calendar times as the default measurement periods, which may not adequately account for individual variations in sleep patterns. To address this, experts in sleep medicine and wearables developed a user-centric algorithm that more accurately reflects actual sleep behaviors, aiming to improve wearable-derived sleep metrics. Objective: The study aimed to describe the development of the new (user-centric) algorithm, and how it compares with the default (calendar-relative), and offers a practical guide for analyzing All of Us Fitbit sleep data on a cloud platform. Methods: The default and new algorithms was implemented to pre-process and then compute sleep metrics related to schedule, duration, and disturbances using high-resolution Fitbit sleep data from 8,563 participants (median age 58.1 years, 72% female) in the All of Us Research Program (v7 Controlled Tier). Variation in typical sleep patterns was computed by taking the differences in the mean number of primary sleep logs classified by each algorithm. Linear mixed-effects models were used to compare differences in sleep metrics across quartiles of variation in typical sleep patterns. Results: Out of 8,452,630 total sleep logs over a median of 4.2 years of Fitbit monitoring, 401,777 (5%) non-primary sleep logs identified by default algorithm were reclassified to primary sleep by the user-centric algorithm. Variation in typical sleep patterns ranged from -0.08 to 1. Among participants with the most variation in typical sleep patterns, the new algorithm identified more total sleep time (by 17.6 minutes; P<0.001), more wake after sleep onset (by 13.9 minutes; P<0.001), and lower sleep efficiency (by 2.0%; P<0.001), on average. There were only modest differences in sleep stage metrics between the two algorithms. Conclusions: The user-centric algorithm captures the natural variability in sleep schedules, offering an alternative way to pre-process and evaluate sleep metrics related to schedule, duration, and disturbances. R package is publicly available to facilitate the implementation of this algorithm for clinical and translational use.
- 24 January 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e71718
Open AccessCapturing Real-World Habitual Sleep Patterns with a Novel User-centric Algorithm to Pre-Process Fitbit Data in the All of Us Research Program: Retrospective observational longitudinal study. (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Commercial wearables like Fitbits quantify sleep metrics using fixed calendar times as the default measurement periods, which may not adequately account for individual variations in sleep patterns. To address this, experts in sleep medicine and wearables developed a user-centric algorithm that more accurately reflects actual sleep behaviors, aiming to improve wearable-derived sleep metrics. Objective: The study aimed to describe the development of the new (user-centric) algorithm, and how it compares with the default (calendar-relative), and offers a practical guide for analyzing All of Us Fitbit sleep data on a cloud platform. Methods: The default and new algorithms was implemented to pre-process and then compute sleep metrics related to schedule, duration, and disturbances using high-resolution Fitbit sleep data from 8,563 participants (median age 58.1 years, 72% female) in the All of Us Research Program (v7 Controlled Tier). Variation in typical sleep patterns was computed by taking the differences in the mean number of primary sleep logs classified by each algorithm. Linear mixed-effects models were used to compare differences in sleep metrics across quartiles of variation in typical sleep patterns. Results: Out of 8,452,630 total sleep logs over a median of 4.2 years of Fitbit monitoring, 401,777 (5%) non-primary sleep logs identified by default algorithm were reclassified to primary sleep by the user-centric algorithm. Variation in typical sleep patterns ranged from -0.08 to 1. Among participants with the most variation in typical sleep patterns, the new algorithm identified more total sleep time (by 17.6 minutes; P<0.001), more wake after sleep onset (by 13.9 minutes; P<0.001), and lower sleep efficiency (by 2.0%; P<0.001), on average. There were only modest differences in sleep stage metrics between the two algorithms. Conclusions: The user-centric algorithm captures the natural variability in sleep schedules, offering an alternative way to pre-process and evaluate sleep metrics related to schedule, duration, and disturbances. R package is publicly available to facilitate the implementation of this algorithm for clinical and translational use.
- Open Access
- 24 January 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Capturing Real-World Habitual Sleep Patterns With a Novel User-Centric Algorithm to Preprocess Fitbit Data in the All of Us Research Program: Retrospective Observational Longitudinal Study (Preprint)
BACKGROUND Commercial wearables such as Fitbit quantify sleep metrics using fixed calendar times as default measurement periods, which may not adequately account for individual variations in sleep patterns. To address this limitation, experts in sleep medicine and wearable technology developed a user-centric algorithm designed to more accurately reflect actual sleep behaviors and improve the validity of wearable-derived sleep metrics. OBJECTIVE This study aims to describe the development of a new user-centric algorithm, compare its performance with the default calendar-relative algorithm, and provide a practical guide for analyzing All of Us Fitbit sleep data on a cloud-based platform. METHODS The default and user-centric algorithms were implemented to preprocess and compute sleep metrics related to schedule, duration, and disturbances using high-resolution Fitbit sleep data from 8563 participants (median age 58.1 years, 6002/8341, 71.96%, female) in the All of Us Research Program (version 7 Controlled Tier). Variations in typical sleep patterns were calculated by examining the differences in the mean number of primary sleep logs classified by each algorithm. Linear mixed-effects models were used to compare differences in sleep metrics across quartiles of variation in typical sleep patterns. RESULTS Out of 8,452,630 total sleep logs collected over a median of 4.2 years of Fitbit monitoring, 401,777 (4.75%) nonprimary sleep logs identified by the default algorithm were reclassified as primary sleep by the user-centric algorithm. Variation in typical sleep patterns ranged from –0.08 to 1. Among participants with the greatest variation in typical sleep patterns, the user-centric algorithm identified significantly more total sleep time (by 17.6 minutes; P<.001), more wake after sleep onset (by 13.9 minutes; P<.001), and lower sleep efficiency (by 2.0%; P<.001), on average. Differences in sleep stage metrics between the 2 algorithms were modest. CONCLUSIONS The user-centric algorithm captures the natural variability in sleep schedules, providing an alternative approach to preprocess and evaluate sleep metrics related to schedule, duration, and disturbances. A publicly available R package facilitates the implementation of this algorithm for clinical and translational research.
- 24 January 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCapturing Real-World Habitual Sleep Patterns With a Novel User-Centric Algorithm to Preprocess Fitbit Data in the All of Us Research Program: Retrospective Observational Longitudinal Study (Preprint)
BACKGROUND Commercial wearables such as Fitbit quantify sleep metrics using fixed calendar times as default measurement periods, which may not adequately account for individual variations in sleep patterns. To address this limitation, experts in sleep medicine and wearable technology developed a user-centric algorithm designed to more accurately reflect actual sleep behaviors and improve the validity of wearable-derived sleep metrics. OBJECTIVE This study aims to describe the development of a new user-centric algorithm, compare its performance with the default calendar-relative algorithm, and provide a practical guide for analyzing All of Us Fitbit sleep data on a cloud-based platform. METHODS The default and user-centric algorithms were implemented to preprocess and compute sleep metrics related to schedule, duration, and disturbances using high-resolution Fitbit sleep data from 8563 participants (median age 58.1 years, 6002/8341, 71.96%, female) in the All of Us Research Program (version 7 Controlled Tier). Variations in typical sleep patterns were calculated by examining the differences in the mean number of primary sleep logs classified by each algorithm. Linear mixed-effects models were used to compare differences in sleep metrics across quartiles of variation in typical sleep patterns. RESULTS Out of 8,452,630 total sleep logs collected over a median of 4.2 years of Fitbit monitoring, 401,777 (4.75%) nonprimary sleep logs identified by the default algorithm were reclassified as primary sleep by the user-centric algorithm. Variation in typical sleep patterns ranged from –0.08 to 1. Among participants with the greatest variation in typical sleep patterns, the user-centric algorithm identified significantly more total sleep time (by 17.6 minutes; P<.001), more wake after sleep onset (by 13.9 minutes; P<.001), and lower sleep efficiency (by 2.0%; P<.001), on average. Differences in sleep stage metrics between the 2 algorithms were modest. CONCLUSIONS The user-centric algorithm captures the natural variability in sleep schedules, providing an alternative approach to preprocess and evaluate sleep metrics related to schedule, duration, and disturbances. A publicly available R package facilitates the implementation of this algorithm for clinical and translational research.
- Open Access
Electronic health record biobank cohort recapitulates an association between the MUC5B promoter polymorphism and ARDS in critically ill adults
Background: Large population-based DNA biobanks linked to electronic health records (EHRs) may provide novel opportunities to identify genetic drivers of ARDS. Research Question: Can we develop an EHR-based algorithm to identify ARDS in a biobank database, and can this validate a previously reported ARDS genetic risk factor? Study Design and Methods: We analyzed two parallel genotyped cohorts: a prospective biomarker cohort of critically ill adults (VALID), and a retrospective cohort of hospitalized participants enrolled in a de-identified EHR biobank (BioVU). ARDS was identified by clinician-investigator review in VALID and an EHR algorithm in BioVU (EHR-ARDS). We tested the association between the MUC5B promoter polymorphism rs35705950 with development of ARDS, and assessed if age modified this genetic association in each cohort. Results: In VALID, 2,795 patients were included, age was 55 [43, 66] (median [IQR]) years, and 718 (25.7%) developed ARDS. In BioVU, 9,025 hospitalized participants were included, age was 60 [48, 70] years, and 1,056 (11.7%) developed EHR-ARDS. We observed a significant age-related interaction effect on ARDS in VALID: among older patients, rs35705950 was associated with increased ARDS risk (OR: 1.44; 95%CI 1.08-1.92; p=0.012) whereas among younger patients this effect was absent (OR: 0.84; 95%CI: 0.62-1.14; p=0.26). In BioVU, rs35705950 was associated with increased risk for EHR-ARDS among all participants (OR: 1.20; 95%CI: 1.00-1.43, p=0.043) and this did not vary by age. The polymorphism was also associated worse oxygenation in mechanically ventilated BioVU participants, but had no association with oxygenation in VALID. Interpretation: The MUC5B promoter polymorphism was associated with ARDS in two cohorts of at-risk adults. Although age-related effect modification was observed only in VALID, BioVU identified a consistent association between MUC5B and ARDS risk regardless of age, and a novel association with oxygenation impairment. Our study highlights the potential for EHR biobanks to enable precision-medicine ARDS studies.
Open AccessElectronic health record biobank cohort recapitulates an association between the MUC5B promoter polymorphism and ARDS in critically ill adults
Background: Large population-based DNA biobanks linked to electronic health records (EHRs) may provide novel opportunities to identify genetic drivers of ARDS. Research Question: Can we develop an EHR-based algorithm to identify ARDS in a biobank database, and can this validate a previously reported ARDS genetic risk factor? Study Design and Methods: We analyzed two parallel genotyped cohorts: a prospective biomarker cohort of critically ill adults (VALID), and a retrospective cohort of hospitalized participants enrolled in a de-identified EHR biobank (BioVU). ARDS was identified by clinician-investigator review in VALID and an EHR algorithm in BioVU (EHR-ARDS). We tested the association between the MUC5B promoter polymorphism rs35705950 with development of ARDS, and assessed if age modified this genetic association in each cohort. Results: In VALID, 2,795 patients were included, age was 55 [43, 66] (median [IQR]) years, and 718 (25.7%) developed ARDS. In BioVU, 9,025 hospitalized participants were included, age was 60 [48, 70] years, and 1,056 (11.7%) developed EHR-ARDS. We observed a significant age-related interaction effect on ARDS in VALID: among older patients, rs35705950 was associated with increased ARDS risk (OR: 1.44; 95%CI 1.08-1.92; p=0.012) whereas among younger patients this effect was absent (OR: 0.84; 95%CI: 0.62-1.14; p=0.26). In BioVU, rs35705950 was associated with increased risk for EHR-ARDS among all participants (OR: 1.20; 95%CI: 1.00-1.43, p=0.043) and this did not vary by age. The polymorphism was also associated worse oxygenation in mechanically ventilated BioVU participants, but had no association with oxygenation in VALID. Interpretation: The MUC5B promoter polymorphism was associated with ARDS in two cohorts of at-risk adults. Although age-related effect modification was observed only in VALID, BioVU identified a consistent association between MUC5B and ARDS risk regardless of age, and a novel association with oxygenation impairment. Our study highlights the potential for EHR biobanks to enable precision-medicine ARDS studies.
- Open Access
- 27 November 2023
- Published by Elsevier in Gastro Hep Advances
- Vol. 3 (2) , 178-180
Sex, Race, and Ethnicity Differences in Patients Presenting With Diverticular Disease at Emergency Departments in the United States: A National Cross-Sectional Study
- 27 November 2023
- Published by Elsevier in Gastro Hep Advances
- Vol. 3 (2) , 178-180
Open AccessSex, Race, and Ethnicity Differences in Patients Presenting With Diverticular Disease at Emergency Departments in the United States: A National Cross-Sectional Study
- 29 September 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (11-12) , 1543-1555
Trends in characteristics, management, and outcomes of patients presenting with gastrointestinal bleeding to emergency departments in the United States from 2006 to 2019
Summary: Background: Recent epidemiologic studies of trends in gastrointestinal bleeding (GIB) provided results through 2014 or earlier and assessed only hospitalised patients, excluding patients presenting to emergency departments (EDs) who are not hospitalised.Aims: To provide the first U.S. nationwide epidemiological evaluation of all patients presenting to EDs with GIBMethods: We used the Nationwide Emergency Department Sample for 2006–2019 to calculate yearly projected incidence of patients presenting to EDs with primary diagnoses of GIB, categorised by location and aetiology. Outcomes were assessed with multivariable analyses.Results: The age/sex‐adjusted incidence for GIB increased from 378.4 to 397.5/100,000 population from 2006 to 2019. Upper gastrointestinal bleeding (UGIB) incidence decreased from 2006 to 2014 (112.3–94.4/100,000) before increasing to 116.2/100,000 by 2019. Lower gastrointestinal bleeding (LGIB) incidence increased from 2006 to 2015 (146.0 to 161.0/100,000) before declining to 150.2/100,000 by 2019. The proportion of cases with one or more comorbidities increased from 27.4% to 35.9% from 2006 to 2019. Multivariable analyses comparing 2019 to 2006 showed increases in ED discharges (odds ratio [OR] = 1.45; 95% confidence interval [CI] = 1.43–1.48) and decreases in red blood cell (RBC) transfusions (OR = 0.62; 0.61–0.63), endoscopies (OR = 0.60; 0.59–0.61), death (OR = 0.51; 0.48–0.54) and length of stay (relative ratio [RR] = 0.81; 0.80–0.82). Inpatient cost decreased from 2012 to 2019 (RR = 0.92; 0.91–0.93).Conclusions: The incidence of GIB in the U.S. is increasing. UGIB incidence has been increasing since 2014 while LGIB incidence has been decreasing since 2015. Despite a more comorbid population in 2019, case fatality rate, length of stay and costs have decreased. More patients are discharged from the ED and the rate of RBC transfusions has decreased, possibly reflecting changing clinical practice in response to updated guidelines.
- 29 September 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 56 (11-12) , 1543-1555
Trends in characteristics, management, and outcomes of patients presenting with gastrointestinal bleeding to emergency departments in the United States from 2006 to 2019
Summary: Background: Recent epidemiologic studies of trends in gastrointestinal bleeding (GIB) provided results through 2014 or earlier and assessed only hospitalised patients, excluding patients presenting to emergency departments (EDs) who are not hospitalised.Aims: To provide the first U.S. nationwide epidemiological evaluation of all patients presenting to EDs with GIBMethods: We used the Nationwide Emergency Department Sample for 2006–2019 to calculate yearly projected incidence of patients presenting to EDs with primary diagnoses of GIB, categorised by location and aetiology. Outcomes were assessed with multivariable analyses.Results: The age/sex‐adjusted incidence for GIB increased from 378.4 to 397.5/100,000 population from 2006 to 2019. Upper gastrointestinal bleeding (UGIB) incidence decreased from 2006 to 2014 (112.3–94.4/100,000) before increasing to 116.2/100,000 by 2019. Lower gastrointestinal bleeding (LGIB) incidence increased from 2006 to 2015 (146.0 to 161.0/100,000) before declining to 150.2/100,000 by 2019. The proportion of cases with one or more comorbidities increased from 27.4% to 35.9% from 2006 to 2019. Multivariable analyses comparing 2019 to 2006 showed increases in ED discharges (odds ratio [OR] = 1.45; 95% confidence interval [CI] = 1.43–1.48) and decreases in red blood cell (RBC) transfusions (OR = 0.62; 0.61–0.63), endoscopies (OR = 0.60; 0.59–0.61), death (OR = 0.51; 0.48–0.54) and length of stay (relative ratio [RR] = 0.81; 0.80–0.82). Inpatient cost decreased from 2012 to 2019 (RR = 0.92; 0.91–0.93).Conclusions: The incidence of GIB in the U.S. is increasing. UGIB incidence has been increasing since 2014 while LGIB incidence has been decreasing since 2015. Despite a more comorbid population in 2019, case fatality rate, length of stay and costs have decreased. More patients are discharged from the ED and the rate of RBC transfusions has decreased, possibly reflecting changing clinical practice in response to updated guidelines.
- Open Access
- 21 September 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6767-6776
Racial disparity in taxane‐induced neutropenia among cancer patients
Background Large interindividual variations have been reported in chemotherapy-induced toxicities. Little is known whether racial disparities exist in neutropenia associated with taxanes. Methods Patients with a diagnosis of primary cancer who underwent chemotherapy with taxanes were identified from Vanderbilt University Medical Center's Synthetic Derivative. Multinomial regression models were applied to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) of neutropenia associated with race, with adjustments for demographic variables, baseline neutrophil count, chemotherapy-related information, prior treatments, and cancer site. Results A total of 3492 patients were included in the study. Compared with White patients, grade 2 or higher neutropenia was more frequently recorded among Black patients who received taxanes overall (42.2% vs. 32.7%, p < 0.001) or paclitaxel (43.0% vs. 36.7%, p < 0.001) but not among those who received docetaxel (32.0% vs. 30.2%, p = 0.821). After adjustments for multiple covariates, Black patients who received chemotherapy with any taxanes had significantly higher risk of grade 2 (OR = 1.53; 95% CI = 1.09–2.14) and grade 3 (OR = 1.91; 95% CI = 1.36–2.67) neutropenia but comparable risk of grade 4 neutropenia (OR = 1.19; 95% CI = 0.79–1.79). Similar association patterns were observed for Black patients who specifically received paclitaxel, but a null association was found for those treated with docetaxel. Conclusion Black cancer patients treated with taxanes for any cancer had a higher risk of neutropenia compared with their White counterparts, especially those who received paclitaxel. More research is needed to understand the mechanism(s) underlying this racial disparity in order to enhance the delivery of patient-centered oncology.
- 21 September 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6767-6776
Open AccessRacial disparity in taxane‐induced neutropenia among cancer patients
Background Large interindividual variations have been reported in chemotherapy-induced toxicities. Little is known whether racial disparities exist in neutropenia associated with taxanes. Methods Patients with a diagnosis of primary cancer who underwent chemotherapy with taxanes were identified from Vanderbilt University Medical Center's Synthetic Derivative. Multinomial regression models were applied to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) of neutropenia associated with race, with adjustments for demographic variables, baseline neutrophil count, chemotherapy-related information, prior treatments, and cancer site. Results A total of 3492 patients were included in the study. Compared with White patients, grade 2 or higher neutropenia was more frequently recorded among Black patients who received taxanes overall (42.2% vs. 32.7%, p < 0.001) or paclitaxel (43.0% vs. 36.7%, p < 0.001) but not among those who received docetaxel (32.0% vs. 30.2%, p = 0.821). After adjustments for multiple covariates, Black patients who received chemotherapy with any taxanes had significantly higher risk of grade 2 (OR = 1.53; 95% CI = 1.09–2.14) and grade 3 (OR = 1.91; 95% CI = 1.36–2.67) neutropenia but comparable risk of grade 4 neutropenia (OR = 1.19; 95% CI = 0.79–1.79). Similar association patterns were observed for Black patients who specifically received paclitaxel, but a null association was found for those treated with docetaxel. Conclusion Black cancer patients treated with taxanes for any cancer had a higher risk of neutropenia compared with their White counterparts, especially those who received paclitaxel. More research is needed to understand the mechanism(s) underlying this racial disparity in order to enhance the delivery of patient-centered oncology.
- Open Access
- 1 June 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (6) , e1009593
High-throughput framework for genetic analyses of adverse drug reactions using electronic health records
Understanding the contribution of genetic variation to drug response can improve the delivery of precision medicine. However, genome-wide association studies (GWAS) for drug response are uncommon and are often hindered by small sample sizes. We present a high-throughput framework to efficiently identify eligible patients for genetic studies of adverse drug reactions (ADRs) using “drug allergy” labels from electronic health records (EHRs). As a proof-of-concept, we conducted GWAS for ADRs to 14 common drug/drug groups with 81,739 individuals from Vanderbilt University Medical Center’s BioVU DNA Biobank. We identified 7 genetic loci associated with ADRs at P < 5 × 10−8, including known genetic associations such as CYP2D6 and OPRM1 for CYP2D6-metabolized opioid ADR. Additional expression quantitative trait loci and phenome-wide association analyses added evidence to the observed associations. Our high-throughput framework is both scalable and portable, enabling impactful pharmacogenomic research to improve precision medicine.
- 1 June 2021
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 17 (6) , e1009593
Open AccessHigh-throughput framework for genetic analyses of adverse drug reactions using electronic health records
Understanding the contribution of genetic variation to drug response can improve the delivery of precision medicine. However, genome-wide association studies (GWAS) for drug response are uncommon and are often hindered by small sample sizes. We present a high-throughput framework to efficiently identify eligible patients for genetic studies of adverse drug reactions (ADRs) using “drug allergy” labels from electronic health records (EHRs). As a proof-of-concept, we conducted GWAS for ADRs to 14 common drug/drug groups with 81,739 individuals from Vanderbilt University Medical Center’s BioVU DNA Biobank. We identified 7 genetic loci associated with ADRs at P < 5 × 10−8, including known genetic associations such as CYP2D6 and OPRM1 for CYP2D6-metabolized opioid ADR. Additional expression quantitative trait loci and phenome-wide association analyses added evidence to the observed associations. Our high-throughput framework is both scalable and portable, enabling impactful pharmacogenomic research to improve precision medicine.
- Open Access
- 24 September 2020
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 27 (11) , 1675-1687
PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records
Developing algorithms to extract phenotypes from electronic health records (EHRs) can be challenging and time-consuming. We developed PheMap, a high-throughput phenotyping approach that leverages multiple independent, online resources to streamline the phenotyping process within EHRs. PheMap is a knowledge base of medical concepts with quantified relationships to phenotypes that have been extracted by natural language processing from publicly available resources. PheMap searches EHRs for each phenotype’s quantified concepts and uses them to calculate an individual’s probability of having this phenotype. We compared PheMap to clinician-validated phenotyping algorithms from the Electronic Medical Records and Genomics (eMERGE) network for type 2 diabetes mellitus (T2DM), dementia, and hypothyroidism using 84 821 individuals from Vanderbilt Univeresity Medical Center's BioVU DNA Biobank. We implemented PheMap-based phenotypes for genome-wide association studies (GWAS) for T2DM, dementia, and hypothyroidism, and phenome-wide association studies (PheWAS) for variants in FTO, HLA-DRB1, and TCF7L2. In this initial iteration, the PheMap knowledge base contains quantified concepts for 841 disease phenotypes. For T2DM, dementia, and hypothyroidism, the accuracy of the PheMap phenotypes were >97% using a 50% threshold and eMERGE case-control status as a reference standard. In the GWAS analyses, PheMap-derived phenotype probabilities replicated 43 of 51 previously reported disease-associated variants for the 3 phenotypes. For 9 of the 11 top associations, PheMap provided an equivalent or more significant P value than eMERGE-based phenotypes. The PheMap-based PheWAS showed comparable or better performance to a traditional phecode-based PheWAS. PheMap is publicly available online. PheMap significantly streamlines the process of extracting research-quality phenotype information from EHRs, with comparable or better performance to current phenotyping approaches.
- 24 September 2020
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 27 (11) , 1675-1687
Open AccessPheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records
Developing algorithms to extract phenotypes from electronic health records (EHRs) can be challenging and time-consuming. We developed PheMap, a high-throughput phenotyping approach that leverages multiple independent, online resources to streamline the phenotyping process within EHRs. PheMap is a knowledge base of medical concepts with quantified relationships to phenotypes that have been extracted by natural language processing from publicly available resources. PheMap searches EHRs for each phenotype’s quantified concepts and uses them to calculate an individual’s probability of having this phenotype. We compared PheMap to clinician-validated phenotyping algorithms from the Electronic Medical Records and Genomics (eMERGE) network for type 2 diabetes mellitus (T2DM), dementia, and hypothyroidism using 84 821 individuals from Vanderbilt Univeresity Medical Center's BioVU DNA Biobank. We implemented PheMap-based phenotypes for genome-wide association studies (GWAS) for T2DM, dementia, and hypothyroidism, and phenome-wide association studies (PheWAS) for variants in FTO, HLA-DRB1, and TCF7L2. In this initial iteration, the PheMap knowledge base contains quantified concepts for 841 disease phenotypes. For T2DM, dementia, and hypothyroidism, the accuracy of the PheMap phenotypes were >97% using a 50% threshold and eMERGE case-control status as a reference standard. In the GWAS analyses, PheMap-derived phenotype probabilities replicated 43 of 51 previously reported disease-associated variants for the 3 phenotypes. For 9 of the 11 top associations, PheMap provided an equivalent or more significant P value than eMERGE-based phenotypes. The PheMap-based PheWAS showed comparable or better performance to a traditional phecode-based PheWAS. PheMap is publicly available online. PheMap significantly streamlines the process of extracting research-quality phenotype information from EHRs, with comparable or better performance to current phenotyping approaches.
- Open Access
- 21 May 2019
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 3 (2) , pkz017
Soy Food Consumption, Exercise, and Body Mass Index and Osteoporotic Fracture Risk Among Breast Cancer Survivors: The Shanghai Breast Cancer Survival Study
Breast cancer survivors have a high incidence of osteoporosis-related fractures; the associated factors are understudied. We investigated incidence of bone fracture and its associations with soy food consumption, exercise, and body mass index among breast cancer survivors. This prospective study included 4139 stage 0–III breast cancer patients and 1987 pre-/perimenopausal and 2152 postmenopausal patients. Fractures were assessed at 18 months and at 3, 5, and 10 years after cancer diagnosis. Osteoporotic fractures were defined as fractures caused by falls from standing height and at sites associated with osteoporosis. Exercise and soy isoflavone intake were assessed at 6 and 18 months postdiagnosis. Weight and height were measured at baseline. Lifetable and Cox regression analyses were employed. All statistical tests were two sided. The 10-year incidence for osteoporotic fractures was 2.9% and 4.4% for pre-/perimenopausal and postmenopausal patients, respectively. High soy isoflavone intake was associated with reduced risk among pre-/perimenopausal patients (hazard ratio [HR] = 0.22, 95% confidence interval [CI] = 0.09 to 0.53, for soy isoflavone mg/d ≥56.06 vs Ptrend < .001) but not among postmenopausal patients (Pinteraction < .01). Overweight (vs normal weight) was a risk factor for pre-/perimenopausal patients (HR = 1.81, 95% CI = 1.04 to 3.14) but not for postmenopausal patients (HR = 0.67, 95% CI = 0.43 to 1.03; Pinteraction = .01). Exercise was inversely associated with osteoporotic fractures in postmenopausal patients (HR = 0.56, 95% CI = 0.33 to 0.97, for metabolic equivalents hours ≥12.6 vs Ptrend = .035), an association not modified by menopausal status. Our findings, especially the novel association of soy food intake with osteoporotic fractures in breast cancer survivors, if confirmed, can help guide future strategies for fracture risk reduction in this vulnerable population.
- 21 May 2019
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 3 (2) , pkz017
Open AccessSoy Food Consumption, Exercise, and Body Mass Index and Osteoporotic Fracture Risk Among Breast Cancer Survivors: The Shanghai Breast Cancer Survival Study
Breast cancer survivors have a high incidence of osteoporosis-related fractures; the associated factors are understudied. We investigated incidence of bone fracture and its associations with soy food consumption, exercise, and body mass index among breast cancer survivors. This prospective study included 4139 stage 0–III breast cancer patients and 1987 pre-/perimenopausal and 2152 postmenopausal patients. Fractures were assessed at 18 months and at 3, 5, and 10 years after cancer diagnosis. Osteoporotic fractures were defined as fractures caused by falls from standing height and at sites associated with osteoporosis. Exercise and soy isoflavone intake were assessed at 6 and 18 months postdiagnosis. Weight and height were measured at baseline. Lifetable and Cox regression analyses were employed. All statistical tests were two sided. The 10-year incidence for osteoporotic fractures was 2.9% and 4.4% for pre-/perimenopausal and postmenopausal patients, respectively. High soy isoflavone intake was associated with reduced risk among pre-/perimenopausal patients (hazard ratio [HR] = 0.22, 95% confidence interval [CI] = 0.09 to 0.53, for soy isoflavone mg/d ≥56.06 vs Ptrend < .001) but not among postmenopausal patients (Pinteraction < .01). Overweight (vs normal weight) was a risk factor for pre-/perimenopausal patients (HR = 1.81, 95% CI = 1.04 to 3.14) but not for postmenopausal patients (HR = 0.67, 95% CI = 0.43 to 1.03; Pinteraction = .01). Exercise was inversely associated with osteoporotic fractures in postmenopausal patients (HR = 0.56, 95% CI = 0.33 to 0.97, for metabolic equivalents hours ≥12.6 vs Ptrend = .035), an association not modified by menopausal status. Our findings, especially the novel association of soy food intake with osteoporotic fractures in breast cancer survivors, if confirmed, can help guide future strategies for fracture risk reduction in this vulnerable population.